 |
|
|
| |
The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH)
|
| |
| |
AIDS 2020 VIRTUAL
6-10 July 2020
Reported by Jules Levin
O. Robineau1, S. Esser2, C. Spinner3, C. Stephan4, J. Brunetta5, J. De Wet6, A. Wong7, B. van Welzen8, J.S. Lambert9, M. Heinzkill10, H. Ramroth11, S. Sahali12, H. Tossonian13, A. Torres Cornejo14, N. Marshall15, R. Haubrich16, D. Thorpe11
1University of Lille, Hospital of Tourcoing, Tourcoing, France; 2University Hospital Essen, Essen, Germany; 3Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Munich, Germany; 4University Hospital Frankfurt, Medical Clinic II, Frankfurt, Germany; 5Maple Leaf Medical Clinic, Toronto, Canada, 6Spectrum Health, Vancouver, Canada; 7University of Saskatchewan, Regina General Hospital, Regina, Canada; 8University Medical Centre, Utrecht, Netherlands; 9Mater Misericordiae University Hospital, Dublin, Ireland; 10Gilead Sciences GmbH, Munich, Germany; 11Gilead Sciences Europe Ltd, Stockley Park, UK, 12Gilead Sciences Inc, Boulogne-Billancourt, France; 13Gilead Sciences Canada Inc, Ontario, Canada; 14Gilead Sciences, Amsterdam, Netherlands; 15Gilead Sciences Ltd, London, UK; 16Gilead Sciences USA, Foster City, USA
|
| |
|
|
|
|
|
